The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Editor

Share

Personal info

View

Links

Table of contents

About

Terms

 

Horng H. Chen

Cardiorenal Research Laboratory

Division of Cardiovascular Diseases

Mayo Clinic and Foundation

Rochester

Minnesota. Electronic address:

[email]@mayo.edu

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • Cardiorenal Research Laboratory, Division of Cardiovascular Diseases, Mayo Clinic and Foundation, Rochester, Minnesota. Electronic address:. 1999 - 2012
  • Department of Internal Medicine, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA. 2000 - 2009
  • Cardiorenal Research Laboratory, Mayo Clinic, Rochester, MN 55904, USA. 2009
  • Cardiorenal Research Laboratory, Guggenheim 915, Mayo Clinic and Foundation, 200 First St SW, USA. 2005 - 2006
  • Mayo Clinic College of Medicine, Rochester, MN 55905, USA. 2006

References

  1. Novel protein therapeutics for systolic heart failure: chronic subcutaneous B-type natriuretic Peptide. Chen, H.H., Glockner, J.F., Schirger, J.A., Cataliotti, A., Redfield, M.M., Burnett, J.C. J. Am. Coll. Cardiol. (2012) [Pubmed]
  2. Local renal delivery of a natriuretic peptide a renal-enhancing strategy for B-type natriuretic peptide in overt experimental heart failure. Chen, H.H., Cataliotti, A., Schirger, J.A., Martin, F.L., Harstad, L.K., Burnett, J.C. J. Am. Coll. Cardiol. (2009) [Pubmed]
  3. Low-dose nesiritide in human anterior myocardial infarction suppresses aldosterone and preserves ventricular function and structure: a proof of concept study. Chen, H.H., Martin, F.L., Gibbons, R.J., Schirger, J.A., Wright, R.S., Schears, R.M., Redfield, M.M., Simari, R.D., Lerman, A., Cataliotti, A., Burnett, J.C. Heart (2009) [Pubmed]
  4. Low dose nesiritide and the preservation of renal function in patients with renal dysfunction undergoing cardiopulmonary-bypass surgery: a double-blind placebo-controlled pilot study. Chen, H.H., Sundt, T.M., Cook, D.J., Heublein, D.M., Burnett, J.C. Circulation (2007) [Pubmed]
  5. Intact acute cardiorenal and humoral responsiveness following chronic subcutaneous administration of the cardiac peptide BNP in experimental heart failure. Chen, H.H., Schirger, J.A., Cataliotti, A., Burnett, J.C. Eur. J. Heart Fail. (2006) [Pubmed]
  6. Maximizing the renal cyclic 3'-5'-guanosine monophosphate system with type V phosphodiesterase inhibition and exogenous natriuretic peptide: a novel strategy to improve renal function in experimental overt heart failure. Chen, H.H., Huntley, B.K., Schirger, J.A., Cataliotti, A., Burnett, J.C. J. Am. Soc. Nephrol. (2006) [Pubmed]
  7. Pathophysiology of volume overload in acute heart failure syndromes. Chen, H.H., Schrier, R.W. Am. J. Med. (2006) [Pubmed]
  8. Therapeutic potential for existing and novel forms of natriuretic peptides. Chen, H.H., Burnett, J.C. Heart. Failure. Clinics (2006) [Pubmed]
  9. Equimolar doses of atrial and brain natriuretic peptides and urodilatin have differential renal actions in overt experimental heart failure. Chen, H.H., Cataliotti, A., Schirger, J.A., Martin, F.L., Burnett, J.C. Am. J. Physiol. Regul. Integr. Comp. Physiol. (2005) [Pubmed]
  10. Angiotensin II AT1 receptor antagonism prevents detrimental renal actions of acute diuretic therapy in human heart failure. Chen, H.H., Redfield, M.M., Nordstrom, L.J., Cataliotti, A., Burnett, J.C. Am. J. Physiol. Renal Physiol. (2003) [Pubmed]
  11. Maximizing the natriuretic peptide system in experimental heart failure: subcutaneous brain natriuretic peptide and acute vasopeptidase inhibition. Chen, H.H., Lainchbury, J.G., Harty, G.J., Burnett, J.C. Circulation (2002) [Pubmed]
  12. Natriuretic peptide receptors and neutral endopeptidase in mediating the renal actions of a new therapeutic synthetic natriuretic peptide dendroaspis natriuretic peptide. Chen, H.H., Lainchbury, J.G., Burnett, J.C. J. Am. Coll. Cardiol. (2002) [Pubmed]
  13. Endogenous natriuretic peptides participate in renal and humoral actions of acute vasopeptidase inhibition in experimental mild heart failure. Chen, H.H., Lainchbury, J.G., Matsuda, Y., Harty, G.J., Burnett, J.C. Hypertension (2001) [Pubmed]
  14. The modulating actions of sulfonylurea on atrial natriuretic peptide release in experimental acute heart failure. Chen, H.H., Oh, K.Y., Terzic, A., Burnett, J.C. Eur. J. Heart Fail. (2000) [Pubmed]
  15. Natriuretic peptides in the pathophysiology of congestive heart failure. Chen, H.H., Burnett, J.C. Curr. Cardiol. Rep (2000) [Pubmed]
  16. Subcutaneous administration of brain natriuretic peptide in experimental heart failure. Chen, H.H., Grantham, J.A., Schirger, J.A., Jougasaki, M., Redfield, M.M., Burnett, J.C. J. Am. Coll. Cardiol. (2000) [Pubmed]
  17. Renal response to acute neutral endopeptidase inhibition in mild and severe experimental heart failure. Chen, H.H., Schirger, J.A., Chau, W.L., Jougasaki, M., Lisy, O., Redfield, M.M., Barclay, P.T., Burnett, J.C. Circulation (1999) [Pubmed]
 
WikiGenes - Universities